V+PSF-M for Tobacco Cessation in HIV Care in India
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Colorado, Denver
About this trial
The goal of this research study is to test an intervention to help quit tobacco use in participants with Human Immunodeficiency Virus (HIV).
The study interventions used in this research study are:
* Positively Smoke Free - Mobile (PSF-M) (mobile behavioral program) * Varenicline (or Chantix, apovarenicline, Champix or Nocrav)
Eligibility criteria
Qualifiers
Adults (≥18 years)
Confirmed HIV diagnosis
Self-reported current smoking or dual tobacco use verified either by exhaled carbon monoxide ≥7 ppm, or by positive qualitative cotinine point-of-care test
Able to read at 6th grade level or greater and speak Tamil, Telugu or English
Disqualifiers
Pregnant or planning to become pregnant in the next 6 months
Breastfeeding
Myocardial infarction in past 30 days or unstable angina
History of liver or kidney failure
Trial design
Treatments tested in this trial
- Varenicline
- Positively Smoke Free Mobile (PSF-M)
- Standard Care
Treatment groups
400 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Colorado, Denver
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov